|Courtesy of ReCor Medical|
What To Know: ReCor Medical is the second privately held operation with a CE marked renal denervation device, but unlike Vessix Vascular and the rest of the group, ReCor uses ultrasound energy to deaden nerves in the kidney. The Paradise catheter is inserted into the renal artery and, when activated, emits high-frequency sound waves that increase temperatures in the surrounding tissues enough to do the necessary nerve damage, all without marring the arterial wall. In a recent study, ReCor reported that its novel device reduced blood pressure by an average of 33 mm Hg in hypertensive patients. The company is backed by Sofinnova Ventures.
What's Next: ReCor completed enrollment of its 15-patient first-in-man study earlier this year, using those positive results to get a CE mark in February. Now, the company is enrolling 20 patients for a second study in France, and ReCor is planning a post-market surveillance study later this year, looking to drive market adoption in Europe.
Release: ReCor reports follow-up results in Paradise trial
Release: ReCor Medical gets CE mark for Paradise